Clarity Pharmaceuticals (ASX:CU6) Preferred Dividends: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
36 GF Score
Price A$2.45
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Preferred Dividends?

Clarity Pharmaceuticals ASX:CU6 36 Preferred Dividends is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Clarity Pharmaceuticals's preferred dividends for the six months ended in Dec. 2025 was A$0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Clarity Pharmaceuticals  (ASX:CU6) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Preferred Dividends Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Preferred Dividends Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Preferred Dividends
0.00 0.00 0.00 0.00

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CU6
36GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Preferred Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Frequently Asked Questions Learn more about Preferred Dividends →
What does a Preferred Dividends of A$0.00 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Preferred Dividends of A$0.00 Mil as of Dec. 2025. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Preferred Dividends too high?
Clarity Pharmaceuticals' current Preferred Dividends is A$0.00 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Preferred Dividends compare to VRTX and REGN?
Clarity Pharmaceuticals' Preferred Dividends of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Dividends for a Biotechnology company?
A good Preferred Dividends depends on the Biotechnology industry context. However, Preferred Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Dividends mean?
A high Preferred Dividends can signal that a stock is expensive relative to its fundamentals. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Preferred Dividends is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Preferred Dividends of A$0.00 Mil. The current Preferred Dividends is A$0.00 Mil. Clarity Pharmaceuticals' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Dividends calculated?
Preferred Dividends is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Preferred Dividends is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
36GF Score

Get the complete analysis for ASX:CU6

Preferred Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.45
Price